Guidant recently released information about its cardiac devices, providing confirmed failure details by product family.
The company's cardiac rhythm management product performance report contains information on clinical manifestations and causes for patterns of failures. Guidant also characterizes these failures to describe therapy available.
"We understand that patients, physicians and others are requesting additional information related to product performance," said Fred McCoy, president of Cardiac Rhythm Management at Guidant. "Our updated CRM Product Performance Report delivers an unprecedented level of relevant product performance information in a single, readily-accessible report."
The company's decision to release this data comes as Guidant is facing legal troubles stemming from the company's handling of problems with its implantable cardioverter defibrillators. That dispute led Johnson & Johnson to reconsider a $25.4 billion deal to purchase the company. Guidant recently sued to force the merger.
()a href="http://www.fdanews.com/ddl" target=_blank>